Washington, Dec 29 (PTI) India-US cooperation in the health sector is in the news as the Central Drugs Authority (CDA) this week approved two more anti-Covid-19 vaccines – Corbevax and Kovovax – and antiviral drug mollupirvir for use in India. Approved.
India’s Ambassador to the US Taranjit Singh Sandhu in a tweet called it a model of Indo-US health cooperation. “India-US health cooperation models can achieve the goal of global well-being,” Sandhu said.
Texas Children’s, Indian companies working with Baylor College of Medicine’s National School of Tropical Medicine, Dr. Peter Hotez, Professor and Dean of the National School of Tropical Medicine in Baylor, Texas Children’s Hospital Center for Vaccine Development, Co-Director of Novavax Merck & Ridgeback Bio retweeted the Indian diplomat’s tweet.
During his visit to Houston in October, Sandhu had met Professor Hotez and discussed the issue. In June this year, the ambassador visited the Novavax center in Maryland. He also spoke to Sanisure CEO Thomas Hook. SaniSure supplies components for the SII-Novavax collaboration.
Corbevax, an anti-COVID-19 vaccine made from a protein subunit, has been developed in collaboration with Texas Children’s Hospital and Baylor College of Medicine. Corbevax has received Emergency Use Authority (EUA) approval from the Drug Controller General of India (DCGI). Texas Children’s Hospital said in a statement that it is being started in India along with other needy countries.
It has been called the “world’s anti-Covid-19 vaccine”, the statement said. It uses a traditional protein-based technology whose mass production will enable widespread vaccination of the global population.
After completing phase two of the investigation, the third phase of Corbevax included more than 3,000 participants who were found to develop better immunity and did not have any problems.